|
Market Closed -
Other stock markets
|
After hours 20:58:00 | |||
| 18.78 EUR | +1.19% |
|
18.78 | 0.00% |
| 03-19 | Formycon Enters Licensing Deal for Eylea Biosimilars | MT |
| 03-19 | Formycon says co secures license date for Fyb203 biosimilar in Europe & further territories | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | -5.93M | -13.48M | 35.99M | 75.8M | -126M | |||||
Depreciation & Amortization - CF | 691K | 685K | 1.7M | 1.69M | 131M | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 224K | 258K | 42K | 38K | 7.62M | |||||
Depreciation & Amortization, Total | 915K | 943K | 1.74M | 1.72M | 139M | |||||
Amortization of Deferred Charges, Total - (CF) | - | - | 123K | 163K | 197K | |||||
(Gain) Loss From Sale Of Asset | 37K | 175K | 36K | 41K | 163K | |||||
Asset Writedown & Restructuring Costs | - | - | - | - | - | |||||
Stock-Based Compensation (CF) | - | - | 535K | 1.62M | 1.68M | |||||
Other Operating Activities, Total | 134K | 164K | -54.05M | -76.38M | -26.63M | |||||
Change In Accounts Receivable | - | - | 3.08M | -12.7M | -2.73M | |||||
Change In Inventories | -2.48M | -4.68M | -363K | 104K | 206K | |||||
Change In Accounts Payable | 1.95M | 550K | -2.77M | 5M | 1.12M | |||||
Change in Other Net Operating Assets | 269K | 2.15M | -3.2M | -5.22M | -10.41M | |||||
Cash from Operations | -5.1M | -14.18M | -18.88M | -9.85M | -23.22M | |||||
Capital Expenditure | -558K | -704K | -551K | -1.03M | -1.54M | |||||
Sale of Property, Plant, and Equipment | - | - | - | - | 5K | |||||
Cash Acquisitions | - | - | 1.11M | - | - | |||||
Sale (Purchase) of Intangible assets | -92K | -547K | -26.21M | -20.17M | -28.4M | |||||
Investment in Marketable and Equity Securities, Total | - | -2.99M | -11.42M | - | - | |||||
Other Investing Activities, Total | 2K | 2K | 2K | 3.82M | 28.48M | |||||
Cash from Investing | -648K | -4.24M | -37.07M | -17.38M | -1.46M | |||||
Long-Term Debt Issued, Total | - | - | 40M | - | - | |||||
Total Debt Issued | - | - | 40M | - | - | |||||
Long-Term Debt Repaid, Total | - | - | -908K | -24.24M | -42.7M | |||||
Total Debt Repaid | - | - | -908K | -24.24M | -42.7M | |||||
Issuance of Common Stock | 25.75M | 1.51M | 1.76M | 70.49M | 83.09M | |||||
Other Financing Activities, Total | -106K | -166K | -118K | -1.8M | -912K | |||||
Cash from Financing | 25.64M | 1.35M | 40.74M | 44.44M | 39.48M | |||||
Miscellaneous Cash Flow Adjustments | 1K | - | - | - | - | |||||
Net Change in Cash | 19.89M | -17.07M | -15.21M | 17.22M | 14.8M | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 106K | 166K | 118K | 69K | 913K | |||||
Cash Income Tax Paid (Refund) | - | - | 331K | 166K | 4K | |||||
Levered Free Cash Flow | -3.4M | -10.42M | -23.88M | -18.99M | 67.14M | |||||
Unlevered Free Cash Flow | -3.33M | -10.32M | -23.8M | -18.94M | 67.82M | |||||
Change In Net Working Capital | 6.28K | 1.69M | -11.64M | 746K | 28.32M | |||||
Net Debt Issued / Repaid | - | - | 39.09M | -24.24M | -42.7M |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















